NSEI:PANACEABIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Panacea Biotec Limited, a biotechnology company, researches and develops, manufactures, markets, and sells pharmaceuticals, vaccines, and biosimilar in India.

Risk Analysis

Highly volatile share price over past 3 months



Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Panacea Biotec's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PANACEABIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.2%

PANACEABIO

-3.2%

IN Biotechs

1.3%

IN Market


1 Year Return

28.4%

PANACEABIO

52.0%

IN Biotechs

-10.7%

IN Market

Return vs Industry: PANACEABIO underperformed the Indian Biotechs industry which returned 52% over the past year.

Return vs Market: PANACEABIO exceeded the Indian Market which returned -10.7% over the past year.


Shareholder returns

PANACEABIOIndustryMarket
7 Day-3.2%-3.2%1.3%
30 Day33.6%3.1%7.0%
90 Day57.0%35.1%29.4%
1 Year28.4%28.4%52.3%52.0%-9.0%-10.7%
3 Year35.7%35.7%119.7%118.3%0.08%-5.2%
5 Year54.9%54.9%352.2%344.6%23.3%12.0%

Price Volatility Vs. Market

How volatile is Panacea Biotec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Panacea Biotec undervalued compared to its fair value and its price relative to the market?

6.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PANACEABIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PANACEABIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PANACEABIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PANACEABIO is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PANACEABIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PANACEABIO is overvalued based on its PB Ratio (6.1x) compared to the IN Biotechs industry average (3x).


Next Steps

Future Growth

How is Panacea Biotec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Panacea Biotec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Panacea Biotec performed over the past 5 years?

20.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PANACEABIO is currently unprofitable.

Growing Profit Margin: PANACEABIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PANACEABIO is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare PANACEABIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PANACEABIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).


Return on Equity

High ROE: PANACEABIO has a negative Return on Equity (-95.97%), as it is currently unprofitable.


Next Steps

Financial Health

How is Panacea Biotec's financial position?


Financial Position Analysis

Short Term Liabilities: PANACEABIO's short term assets (₹6.8B) exceed its short term liabilities (₹4.6B).

Long Term Liabilities: PANACEABIO's short term assets (₹6.8B) do not cover its long term liabilities (₹7.4B).


Debt to Equity History and Analysis

Debt Level: PANACEABIO's debt to equity ratio (407%) is considered high.

Reducing Debt: PANACEABIO's debt to equity ratio has increased from 233.7% to 407% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if PANACEABIO has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PANACEABIO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Panacea Biotec current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PANACEABIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PANACEABIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PANACEABIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PANACEABIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PANACEABIO is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PANACEABIO's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average management tenure


CEO

Sandeep Jain (54yo)

18.42yrs

Tenure

₹6,700,000

Compensation

Mr. Sandeep Jain has been Joint Managing Director of Panacea Biotec Ltd. since February 1, 2002 and has been its Director since November 15, 1984. Mr. Jain holds B.Com. 


CEO Compensation Analysis

Compensation vs Market: Sandeep's total compensation ($USD89.58K) is below average for companies of similar size in the Indian market ($USD296.31K).

Compensation vs Earnings: Sandeep's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Soshil Jain
Founder & Chairman35.83yrs₹11.19m11.84% 1.4b
Sandeep Jain
Joint MD & Executive Director18.42yrs₹6.70m14.53% 1.7b
Rajesh Jain
MD & Whole-Time Director35.67yrs₹7.30m18.22% 2.2b
Devender Gupta
CFO & Head of Information Technology5.17yrs₹4.37mno data
Vinod Goel
Group CFOno data₹5.62m0.00041% 49.2k
Ankesh Jain
Director of Sales & Marketing and Whole-Time Director4.25yrs₹2.42m0.50% 60.2m
Kulvinder Sarao
Senior Vice President of Auditno datano datano data
Sumit Jain
Director of Operations & Projects and Whole-Time Director15yrs₹4.18m0.59% 70.3m
Sukhjeet Singh
Chief Scientific Officer & RA (Pharma)no datano datano data
Gurinder Singh
Senior VP of Acute & Chronic Businessno datano datano data

11.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: PANACEABIO's management team is seasoned and experienced (11.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Soshil Jain
Founder & Chairman35.83yrs₹11.19m11.84% 1.4b
Sandeep Jain
Joint MD & Executive Director18.42yrs₹6.70m14.53% 1.7b
Rajesh Jain
MD & Whole-Time Director35.67yrs₹7.30m18.22% 2.2b
Ankesh Jain
Director of Sales & Marketing and Whole-Time Director4.25yrs₹2.42m0.50% 60.2m
Sumit Jain
Director of Operations & Projects and Whole-Time Director15yrs₹4.18m0.59% 70.3m
Sunanda Jain
Whole Time Director2.33yrs₹5.80m10.85% 1.3b
Raghava Narasimhan
Non-Executive Independent Director19.5yrs₹330.00kno data
Namdeo Khamitkar
Non-Executive Independent Director14.5yrs₹310.00kno data
Krishna Lal
Non-Executive Independent Director14.25yrs₹270.00kno data
Manjula Upadhyay
Non-Executive Independent Director5.33yrs₹250.00kno data

14.8yrs

Average Tenure

63yo

Average Age

Experienced Board: PANACEABIO's board of directors are seasoned and experienced ( 14.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Panacea Biotec Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Panacea Biotec Limited
  • Ticker: PANACEABIO
  • Exchange: NSEI
  • Founded: 1984
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹12.008b
  • Shares outstanding: 61.25m
  • Website: https://www.panaceabiotec.com

Location

  • Panacea Biotec Limited
  • B-1 Extension/G-3
  • Mohan Co-operative Industrial Estate
  • New Delhi
  • Delhi
  • 110044
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
531349BSE (Mumbai Stock Exchange)YesEquity SharesININRApr 1996
PANACEABIONSEI (National Stock Exchange of India)YesEquity SharesININRApr 1996

Biography

Panacea Biotec Limited, a biotechnology company, researches and develops, manufactures, markets, and sells pharmaceuticals, vaccines, and biosimilar in India. The company operates through Vaccines, Formulations, and Research and Development segments. Its product portfolio includes prescription products in various therapeutic areas, including pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care products, as well as vaccines. The company also exports its products to the Commonwealth of Independent States, Africa, the Middle East, and Asia. It has a collaboration agreement with Refana Inc. for the development, manufacturing, and distribution of the Covid-19 vaccine. Panacea Biotec Limited was founded in 1984 and is based in New Delhi, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/03 13:00
End of Day Share Price2020/07/03 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.